A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Rα chain with immune activating and tumoricidal effects in vivo

Molecular Therapy

Volumn 18, Issue 7, 2010, Pages 1293-1301

  Williams, Patrick ^a   Rafei, Moutih ^a   Bouchentouf, Manaf ^a   Raven, Jennifer ^a   Yuan, Shala ^a   Cuerquis, Jessica ^a   Forner, Kathy A ^a   Birman, Elena ^a   Galipeau, Jacques ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR AND INTERLEUKIN 21; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR ALPHA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; IMMUNE RESPONSE; LYMPHOMA; MACROPHAGE; MELANOMA B16; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-21 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

MUS;

EID: 77954242768     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.49     Document Type: Article

References (43)

1. Berzofsky, JA, Terabe, M, Oh, S, Belyakov, IM, Ahlers, JD, Janik, JE et al. (2004). Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 113: 1515-1525. (Pubitemid 39071672)
2. Khong, HT and Restifo, NP (2002). Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3: 999-1005.
3. Nemunaitis, J (2005). Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 4: 259-274.
4. Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specifc, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543.
5. Stagg, J, Wu, JH, Bouganim, N and Galipeau, J (2004). Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 64: 8795-8799.
6. Asao, H, Okuyama, C, Kumaki, S, Ishii, N, Tsuchiya, S, Foster, D et al. (2001). Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 167: 1-5.
7. Korn, T, Bettelli, E, Gao, W, Awasthi, A, Jäger, A, Strom, TB et al. (2007). IL-21 initiates an alternative pathway to induce proinfammatory T(H)17 cells. Nature 448: 484-487.
8. rd (2006). Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 177: 120-129.
9. Casey, KA and Mescher, MF (2007). IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J Immunol 178: 7640-7648.
10. Kishida, T, Asada, H, Itokawa, Y, Cui, FD, Shin-Ya, M, Gojo, S et al. (2003). Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 8: 552-558.
11. Kim-Schulze, S, Kim, HS, Fan, Q, Kim, DW and Kaufman, HL (2009). Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther 17: 380-388.
12. Peluso, I, Fantini, MC, Fina, D, Caruso, R, Boirivant, M, MacDonald, TT et al. (2007). IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 178: 732-739.
13. Li, Y and Yee, C (2008). IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specifc CD8+ cytotoxic T lymphocytes. Blood 111: 229-235.
14. Konforte, D and Paige, CJ (2006). Identifcation of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol 177: 8381-8392.
15. Di Carlo, E, Comes, A, Orengo, AM, Rosso, O, Meazza, R, Musiani, P et al. (2004). IL-21 induces tumor rejection by specifc CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 172: 1540-1547.
16. Rafei, M, Wu, JH, Annabi, B, Lejeune, L, François, M and Galipeau, J (2007). A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood 109: 2234-2242.
17. Eliopoulos, N, Francois, M, Boivin, MN, Martineau, D and Galipeau, J (2008). Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 68: 4810-4818.
18. Ma, HL, Whitters, MJ, Konz, RF, Senices, M, Young, DA, Grusby, MJ et al. (2003). IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 171: 608-615.
19. Søndergaard, H, Frederiksen, KS, Thygesen, P, Galsgaard, ED, Skak, K, Kristjansen, PE et al. (2007). Interleukin 21 therapy increases the density of tumor infltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 56: 1417-1428.
20. Faisal, M, Cumberland, W, Champlin, R and Fahey, JL (1990). Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia. Blood 76: 1580-1585.
21. Sinha, P, Clements, VK, Bunt, SK, Albelda, SM and Ostrand-Rosenberg, S (2007). Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179: 977-983.
22. Rössner, S, Voigtländer, C, Wiethe, C, Hänig, J, Seifarth, C and Lutz, MB (2005). Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 35: 3533-3544.
23. Daley, JM, Brancato, SK, Thomay, AA, Reichner, JS and Albina, JE (2010). The phenotype of murine wound macrophages. J Leukoc Biol 87: 59-67.
24. Fultz, MJ, Barber, SA, Dieffenbach, CW and Vogel, SN (1993). Induction of IFN-gamma in macrophages by lipopolysaccharide. Int Immunol 5: 1383-1392.
25. Hsieh, CS, Macatonia, SE, Tripp, CS, Wolf, SF, O'Garra, A and Murphy, KM (1993). Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
26. Andrade, RM, Wessendarp, M, Portillo, JA, Yang, JQ, Gomez, FJ, Durbin, JE et al. (2005). TNF receptor-associated factor 6-dependent CD40 signaling primes macrophages to acquire antimicrobial activity in response to TNF-alpha. J Immunol 175: 6014-6021.
27. Renauld, JC, Vink, A and Van Snick, J (1989). Accessory signals in murine cytolytic T cell responses. Dual requirement for IL-1 and IL-6. J Immunol 143: 1894-1898.
28. Elices, MJ, Osborn, L, Takada, Y, Crouse, C, Luhowskyj, S, Hemler, ME et al. (1990). VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fbronectin binding site. Cell 60: 577-584.
29. Iademarco, MF, McQuillan, JJ, Rosen, GD and Dean, DC (1992). Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 267: 16323-16329.
30. Yamamoto, M, Yoshizaki, K, Kishimoto, T and Ito, H (2000). IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164: 4878-4882.
31. Alonzi, T, Fattori, E, Lazzaro, D, Costa, P, Probert, L, Kollias, G et al. (1998). Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187: 461-468.
32. Firestein, GS, Alvaro-Gracia, JM, Maki, R and Alvaro-Garcia, JM (1990). Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144: 3347-3353.
33. Ogata, H, Takeya, M, Yoshimura, T, Takagi, K and Takahashi, K (1997). The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J Pathol 182: 106-114.
34. Plater-Zyberk, C, Hoogewerf, AJ, Proudfoot, AE, Power, CA and Wells, TN (1997). Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 57: 117-120.
35. Sukhanov, S, Higashi, Y, Shai, SY, Vaughn, C, Mohler, J, Li, Y et al. (2007). IGF-1 reduces infammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-defcient mice. Arterioscler Thromb Vasc Biol 27: 2684-2690.
36. Pesce, J, Kaviratne, M, Ramalingam, TR, Thompson, RW, Urban, JF Jr, Cheever, AW et al. (2006). The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 116: 2044-2055.
37. Wynes, MW and Riches, DW (2003). Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol 171: 3550-3559.
38. Beltan, E, Horgen, L and Rastogi, N (2000). Secretion of cytokines by human macrophages upon infection by pathogenic and non-pathogenic mycobacteria. Microb Pathog 28: 313-318.
39. Gowda, A, Roda, J, Hussain, SR, Ramanunni, A, Joshi, T, Schmidt, S et al. (2008). IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 111: 4723-4730.
40. Lamprecht, B, Kreher, S, Anagnostopoulos, I, Jöhrens, K, Monteleone, G, Jundt, F et al. (2008). Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112: 3339-3347.
41. Brenne, AT, Fagerli, UM, Shaughnessy, JD Jr, Våtsveen, TK, Rø, TB, Hella, H et al. (2009). High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol 82: 354-363.
42. Penafuerte, C, Bautista-Lopez, N, Mohamed-Rachid, B, Routy, JP and Galipeau, J (2009). The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res 69: 9020-9028.
43. Stagg, J, Lejeune, L, Paquin, A and Galipeau, J (2004). Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 15: 597-608.